The non-Hodgkin lymphoma (NHL) treatment market involves the development and commercialization of therapies and drugs for the treatment of NHL, a type of cancer that affects the lymphatic system. The market is driven by factors such as the increasing prevalence of NHL, the rise in geriatric population, and the development of new therapies with improved efficacy.
The non-Hodgkin lymphoma treatment market is expected to experience significant growth in the coming years due to the increasing prevalence of NHL and the development of new therapies with improved efficacy and fewer side effects.
See the detailed report:
The global “Non-Hodgkin Lymphoma Treatment Market” size is expected to reach USD 12.57 billion by 2026, exhibiting a CAGR of 8.4% during the forecast period, states Fortune Business Insights in a report titled “Non-Hodgkin Lymphoma Treatment Market, 2023-2026.” The market size stood at USD 6.60 billion in 2018.